A Case Report of a Patient With Recalcitrant Pemphigus Vulgaris Treated With Rituximab Authors: Mahlatse Cordelia Kgokolo, Lesedi Makgwethele Nevondo, Michaela Beetge, Razia A G Khammissa Published: 2026 ABSTRACT ABSTRACTPemphigus vulgaris may demonstrate differential treatment responses across disease sites. In this case, cutaneous lesions responded to high‐dose corticosteroids, whereas refractory oral disease required rituximab to achieve remission, highlighting the need for individualized, multimodal therapy to achieve sustained disease control.Keywords: autoimmune blistering diseases, corticosteroids, corticosteroid‐sparing drugs, pemphigus vulgaris, rituximab Introduction Pemphigus vulgaris (PV) is a rare, potentially life‐threatening autoimmune blistering disease caused by IgG autoantibodies targeting desmoglein 3 (mucosal disease) or both desmoglein 1 and 3 (mucocutaneous disease), resulting in acantholysis, flaccid bullae, and erosions of the skin and mucous membranes [1, 2]. Oral mucosal involvement is the initial manifestation in the majority of patients, affecting approximately 90%, with the buccal and labial mucosa most commonly involved [3, 4]. Oral lesions are frequently refractory and carry significant morbidity, impairing nutrition, speech, and quality of life [2]. The disease most commonly presents between the fourth and sixth decades and is diagnosed histopathologically by suprabasal acantholysis, with direct immunofluorescence demonstrating IgG and C3 deposition on keratinocyte surfaces, and serologically by anti‐Dsg1 and anti‐Dsg3 antibodies [5]. Disease severity is assessed using validated tools such as the Pemphigus Disease Area Index [6]. First‐line treatment consists of systemic corticosteroids, often combined with steroid‐sparing immunosuppressants; however, a substantial subset of patients develop refractory disease, particularly with persistent oral lesions. Rituximab, an anti‐CD20 monoclonal antibody that depletes B cells and reduces pathogenic autoantibody production, has emerged as an effective therapy for refractory PV, with randomized controlled trial data supporting its use over conventional immunosuppressants in moderate‐to‐severe disease [7]. We report a case of PV in a 46‐year‐old woman with a 10‐year history of refractory oral lesions that failed to respond to high‐dose corticosteroids, ultimately achieving remission following the initiation of rituximab. Case Report History A 46‐year‐old female patient presented with a 10‐year history of flaccid blisters, many of which ruptured, forming painful erosions and ulcerations involving the trunk and limbs, associated with severe and persistent oral mucosal disease. Oral involvement predominantly affected the tongue (Figure 1) and lower lip (Figure 2), causing significant pain, impaired oral intake, and resultant functional and nutritional compromise. Ulcerative lesion on the dorsum of the tongue. Ulceration with crusting of the lower lip. At initial presentation, clinical examination revealed extensive desquamated, lichenoid‐appearing patches over the trunk, back, thighs, and face, with scattered intact flaccid blisters and prominent oral mucosal erosions. Histopathology and Diagnosis Incisional biopsies obtained from perilesional skin demonstrated suprabasal acantholysis with intraepidermal vesicle formation on hematoxylin and eosin staining (Figures 3 and 4). Direct immunofluorescence findings were consistent with pemphigus vulgaris. An oral mucosal biopsy supported the same diagnosis. Early vesicle formation characterized by suprabasilar keratinocyte acantholysis and tombstone‐like appearance of residual basal cells (x40 magnification). Intraepidermal blister with acantholysis of keratinocytes and suprabasilar tombstone appearance of the basal cells (x40 magnification). Treatment The patient was commenced on high‐dose systemic corticosteroids (prednisone 1 mg/kg/day), resulting in complete resolution of cutaneous lesions. However, the oral mucosal disease persisted and remained refractory (Table 1). Repeated attempts to taper systemic corticosteroids resulted in immediate disease flares, leading to long‐term corticosteroid dependence and associated adverse effects. TABLE 1Summary of treatment administered.TreatmentDoseDurationResponsePrednisone1 mg/kg/day10 monthsComplete resolution of cutaneous lesions; oral mucosal disease persisted and remained refractoryAzathioprine2 mg/kg/day—divided doses6 monthsInadequate clinical response; discontinuedMycophenolate mofetil500 mg daily10 monthsInadequate clinical response; discontinuedRituximab1000 mg IV × 2 infusions, 2 weeks apartInduction phaseMarked clinical improvement of oral mucosal disease; corticosteroids successfully tapered and discontinuedRituximab500 mg IVEvery 6 months (ongoing)Sustained improvement; healing oral erosions; minimal residual erythema; no cutaneous recurrence; nutritional status restored Summary of treatment administered. Multiple steroid‐sparing immunosuppressive agents were trialed over several years. Azathioprine was administered at therapeutic doses on two separate occasions but was discontinued due to inadequate clinical response. Mycophenolate mofetil was subsequently introduced and continued for an extended period, again without satisfactory control of mucosal disease. Despite combination therapy, the patient continued to exhibit persistent oral erosions and ulcerations (Table 1). Given the recalcitrant disease course, significant morbidity, and failure of conventional immunosuppressive therapy, treatment with rituximab was initiated. Pre‐treatment evaluation, including renal and liver function tests, hepatitis viral screening, human immunodeficiency virus testing, and tuberculosis screening, was unremarkable. Age‐appropriate vaccinations were administered prior to therapy. Rituximab was administered according to the rheumatoid arthritis protocol, consisting of two intravenous infusions of 1000 mg given two weeks apart as induction therapy. Results This resulted in marked clinical improvement of the oral mucosal disease (Figures 5 and 6). Systemic corticosteroids were progressively tapered and successfully discontinued by completion of the induction phase. Healed lesion on the dorsum of the tongue. Healed lower lip. The patient was subsequently commenced on rituximab maintenance therapy (Table 1), consisting of additional infusions of 500 mg administered at six‐monthly intervals. At follow‐up, she demonstrated sustained clinical improvement, with healing oral erosions, minimal residual erythema, and no recurrence of cutaneous lesions. Her ability to eat improved significantly, with resolution of nutritional compromise. Discussion The therapeutic management of pemphigus is centered on immunosuppression aimed at preventing new lesion formation, promoting healing of existing erosions, and minimizing treatment‐related adverse effects [2]. Corticosteroids remain the cornerstone of first‐line therapy, administered as monotherapy or combined with adjuvant steroid‐sparing agents such as azathioprine or mycophenolate mofetil, with treatment intensity guided by disease severity [1]. Rituximab, a chimeric anti‐CD20 monoclonal antibody, has emerged as the most effective therapy for pemphigus vulgaris, particularly in refractory disease. By inducing rapid B‐cell depletion through antibody‐dependent cellular cytotoxicity, complement‐mediated lysis, and apoptosis, rituximab disrupts the production of pathogenic anti‐desmoglein autoantibodies, thereby reducing acantholysis and mucocutaneous erosions [8]. Its superiority over conventional immunosuppression was definitively established in the Ritux 3 RCT, in which 89% of patients receiving rituximab achieved complete remission off therapy at 24 months, compared with 34% in the prednisone‐only group [7]. Long‐term observational data have corroborated these findings, with remission rates of 70%–90% sustained over several years, attributed to prolonged B‐cell depletion and repopulation with naive, less autoreactive B cells [9, 10]. Based on this evidence, current European Dermatology Forum and International Pemphigus Committee guidelines recommend rituximab as the preferred first‐line therapy for moderate‐to‐severe PV and the treatment of choice in refractory disease [11]. A clinically important additional benefit is rituximab's steroid‐sparing effect, which significantly reduces cumulative corticosteroid exposure and its associated metabolic, musculoskeletal, cardiovascular, and psychological complications—a consideration of particular relevance in corticosteroid‐dependent patients such as the present case. The safety profile is generally favorable; infusion‐related reactions are typically mild and transient, and long‐term data confirm that repeated cycles are well tolerated with low rates of serious adverse events [12]. Pre‐treatment screening for hepatitis B reactivation, hypogammaglobulinemia, and latent infections is nonetheless recommended [12]. Conclusion The present case illustrates the therapeutic challenges of mucosal‐dominant PV, in which oral lesions—more resistant to treatment than cutaneous manifestations and a major contributor to morbidity and impaired quality of life—persisted for over a decade despite systemic corticosteroids, azathioprine, and mycophenolate mofetil. Sustained disease control was achieved only following the initiation of rituximab, with rapid and marked improvement in both mucosal and cutaneous disease activity, enabling complete cessation of systemic corticosteroids. This outcome is consistent with published evidence and reinforces rituximab's role as a paradigm‐shifting, targeted therapeutic option that offers durable remission while minimizing corticosteroid dependence in refractory pemphigus vulgaris [1, 2, 11]. Author Contributions Mahlatse Cordelia Kgokolo: conceptualization, resources, writing – original draft, writing – review and editing. Lesedi Makgwethele Nevondo: investigation, validation. Michaela Beetge: writing – review and editing. Razia A. G. Khammissa: conceptualization, project administration, writing – original draft, writing – review and editing. Funding The authors have nothing to report. Consent Written informed consent was obtained from the patient to publish this report. Conflicts of Interest The authors declare no conflicts of interest.